Last reviewed · How we verify
Hydroxychloroquine Sulfate Loading Dose
Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.
Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production. Used for Malaria prophylaxis and treatment, Systemic lupus erythematosus (SLE), Rheumatoid arthritis.
At a glance
| Generic name | Hydroxychloroquine Sulfate Loading Dose |
|---|---|
| Sponsor | Government of Punjab, Specialized Healthcare and Medical Education Department |
| Drug class | Antimalarial immunomodulator |
| Target | Toll-like receptors (TLR), lysosomal pH modulation |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Hydroxychloroquine accumulates in lysosomes and endosomes, raising their pH and interfering with antigen presentation and toll-like receptor activation. This reduces the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17, making it effective in autoimmune and inflammatory conditions. The drug also has weak antimalarial properties through inhibition of heme polymerization in Plasmodium parasites.
Approved indications
- Malaria prophylaxis and treatment
- Systemic lupus erythematosus (SLE)
- Rheumatoid arthritis
- COVID-19 (off-label, limited evidence)
Common side effects
- Retinopathy
- Nausea and gastrointestinal upset
- Headache
- Pruritus
- Cardiomyopathy (rare, with high doses)
- Photosensitivity
Key clinical trials
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- HCQ in Resectable Localized Prostate Cancer (EARLY_PHASE1)
- Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD) (PHASE2)
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (PHASE2)
- Hydroxychloroquine in Outpatient Adults With COVID-19 (PHASE1)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 (PHASE2)
- Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: